A two-year retrospective analysis of renal transplant patients in Sri Lanka

• Published in: Saudi journal of kidney diseases and transplantation 2011, Vol.22 (1), p.174-178
• Main Authors: Sharif, Rezvi, Rajapakse, Senaka, Rodrigo, Chaturaka, Sharif, Ricaz, Lanerolle, Rushika D.
• Format: Article
• Language: English
• Subjects: Acute Disease; Care and treatment; Chi-Square Distribution; Communicable Diseases - etiology; Communicable Diseases - mortality; Databases as Topic; Diseases; Drug Therapy, Combination; Female; Graft Rejection - etiology; Graft Rejection - mortality; Humans; Immunosuppressive Agents - adverse effects; Kidney Transplantation - adverse effects; Kidney Transplantation - mortality; Kidneys; Male; Organ transplant recipients; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Sri Lanka - epidemiology; Surveys; Surveys and Questionnaires; Survival Rate; Time Factors; Transplantation; Treatment Outcome; الكلى; المرضى; المضاعفات; زرع الأعضاء
• ISSN: 1319-2442; 2320-3838

This retrospective analytical study aimed at making a database of patients who underwent renal transplant from 31 December 2004 to 31 December 2006 under the Faculty of Medicine renal transplant program. The objective was to build a profile of renal transplant patients with focus on post KT infections and complications of renal transplants. An interviewer administered questionnaire was used. A total of 72 patients were studied; 18 (25%) had died by February 2007. Forty-three patients (58.3%) were interviewed in person, 17 were interviewed over the phone and 12 patients could not be contacted. Of those who were interviewed, 28 (38.9%) were on azathioprine, prednisolone and cyclosporine, while 15 (20.8%) were on predni­solone, cyclosporin and mycophenolate mofetil. Four patients had symptomatic cytomegalovirus infection and five had tuberculosis post transplant. Of all infections, the most commonly reported was urinary tract infection (11 cases). Thirty-three (45.8 %) had received induction therapy with either basiliximab (n = 8) or daclizumab (n = 25). Acute rejection was the most commonly en­countered complication, with nine cases (12.5%) being reported over the study period. Of late complications, most were due to immunosuppression. Overall, the 2-year survival was 75%. There was no significant difference between the centers of transplant.